PMID- 16395488
OWN - NLM
STAT- MEDLINE
DCOM- 20060131
LR  - 20060105
IS  - 0720-9355 (Print)
IS  - 0720-9355 (Linking)
VI  - 25
IP  - 4
DP  - 2005 Nov
TI  - Antithrombotics in thrombosis and cancer.
PG  - 380-6
AB  - Many cancer patients have a hypercoagulable state, with recurrent thrombosis due 
      to the impact of cancer cells and chemotherapy or radiotherapy on the coagulation 
      cascade. Studies have demonstrated that unfractionated heparin (UFH) or its low 
      molecular weight fractions interfere with various processes involved in tumour 
      growth and metastasis. These include fibrin formation; binding of heparin to 
      angiogenic growth factors, such as basic fibroblast growth factor (FGF2) and 
      vascular endothelial growth factor (VEGF); modulation of tissue factor; and 
      perhaps other more important modulatory mechanisms, such as enhanced tissue 
      factor pathway inhibitor (TFPI) release and inhibition of various 
      matrix-degrading enzymes. Clinical trials have suggested a clinically relevant 
      effect of low molecular weight heparin (LMWH), as compared to UFH, on the 
      survival of cancer patients with deep vein thrombosis. Similarly, the impact of 
      warfarin on the survival of cancer patients with thromboembolic disorders was 
      demonstrated. Studies from our laboratory demonstrated a significant role for 
      LMWH, warfarin, anti-VIIa, and LMWH-releasable TFPI on the regulation of 
      angiogenesis, tumour growth, and tumour metastasis. Thus, modulation of tissue 
      factor/VIIa non-coagulant activities by LMWH, warfarin, anti-VIIa, or TFPI might 
      be a useful therapeutic method for the inhibition of angiogenesis associated with 
      human tumour growth and metastasis. Additionally, antiplatelet drugs could have 
      an impact on tumour metastasis, and the combination of antiplatelets and 
      anticoagulants at adjusted doses might provide greater benefits to cancer 
      patients.
FAU - Mousa, S A
AU  - Mousa SA
AD  - Albany College of Pharmacy, 106 New Scotland Avenue Albany, NY 12208-3492, USA. 
      mousas@acp.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Hamostaseologie
JT  - Hamostaseologie
JID - 8204531
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Blood Coagulation
MH  - Blood Platelets/physiology
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Neoplasms/blood/*drug therapy
MH  - Thrombosis/blood/*drug therapy
RF  - 65
EDAT- 2006/01/06 09:00
MHDA- 2006/02/01 09:00
CRDT- 2006/01/06 09:00
PHST- 2006/01/06 09:00 [pubmed]
PHST- 2006/02/01 09:00 [medline]
PHST- 2006/01/06 09:00 [entrez]
AID - 05040380 [pii]
PST - ppublish
SO  - Hamostaseologie. 2005 Nov;25(4):380-6.